This inventor holds 1 USPTO granted patent. Top assignee: Tokyo Metropolitan Institute of Medical Science. Active years: 2024.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2024
Title: Masato Hosokawa: Innovator in Tauopathy Research
Introduction
Masato Hosokawa is a prominent inventor based in Tokyo, Japan. He has made significant contributions to the field of medical science, particularly in the study of tauopathies. His innovative work has led to the development of a novel animal model that aids in understanding these complex diseases.
Latest Patents
Masato Hosokawa holds a patent for a method of producing a novel animal model for tauopathies. This invention provides a disease model animal that reproduces the expression pattern of tau protein isoforms found in the adult human brain. The method involves preparing tau seeds and injecting them into the brain of an animal that carries a mutation in the tau gene, which fails to express the tenth exon. This groundbreaking approach utilizes genome editing, gene targeting, or base editing technologies to create the animal model.
Career Highlights
Hosokawa is affiliated with the Tokyo Metropolitan Institute of Medical Science, where he conducts his research. His work has been instrumental in advancing the understanding of tauopathies, which are neurodegenerative diseases characterized by the abnormal accumulation of tau protein in the brain.
Collaborations
Masato Hosokawa collaborates with esteemed colleagues, including Hiroshi Shitara and Masato Hasegawa. Their combined expertise enhances the research efforts at the Tokyo Metropolitan Institute of Medical Science.
Conclusion
Masato Hosokawa's innovative contributions to tauopathy research exemplify the importance of scientific inquiry in understanding complex diseases. His patented method for producing a novel animal model represents a significant advancement in the field, paving the way for future research and potential therapeutic strategies.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile